Matthew Kronmiller

Matthew (Matt) Kronmiller is a Vice President at Bay City Capital LLC, a San Rafael, California life sciences investment firm, where he has worked since 2011. In his role he is responsible for developing financial analyses, conducting research, and supporting current and potential investments across the firm's core areas of biopharma, diagnostics, healthcare IT, and medical devices. As a Vice President (rather than a Partner or Managing Director), he functions as a deal-support and diligence professional within the investment team rather than as the partner who ultimately leads and signs off on investments.

Before joining Bay City Capital, Kronmiller was an Investment Banking Analyst in the Healthcare group at Bank of America Merrill Lynch, where he advised on a range of M&A and corporate finance transactions for both public and private healthcare clients. That banking background — transaction structuring, valuation, and financial analysis in the healthcare vertical — maps directly onto his diligence and analysis responsibilities at the firm.

He holds a Bachelor of Science in Finance from Pennsylvania State University. Bay City Capital itself was founded in 1997, has raised five venture capital funds representing roughly $1.3 billion in capital commitments, and has invested in approximately 100 portfolio companies across the life sciences. The firm emphasizes long tenure (nearly all partners have been there 12+ years) and a hands-on, board-level partnership model with management teams.

• Bay City Capital invests exclusively in life sciences, with a "global diversified strategy ranging from seed stage to public companies," including innovation, restructuring opportunities, and growth investing.
• Sectors span biopharmaceuticals, drug discovery and research tools, medical devices, diagnostics, healthcare IT, nutrition, and agribusiness.
• The firm seeks companies where its "operational, financial, and scientific expertise can assist management in building companies" — i.e., it favors situations where it can be an active, value-add partner, not a passive check.
• Lead/co-lead posture: the firm has been a lead or co-lead investor 86% of the time (by invested capital) and has taken a board seat at 90% of portfolio companies (by invested capital). It "strongly prefer[s] board representation."
• Syndication strength: 270 investor groups have co-invested alongside Bay City Capital; for every $1.00 the firm invests, an additional ~$3.60 has come from co-investors.
• Exit orientation: M&A is the firm's "primary exit path," and it actively cultivates strategic acquirers — sometimes encouraging them to co-invest early in a company's development.